InflaRx N.V. (IFRX) vs Nature's Sunshine Products (NATR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Nature's Sunshine Products (NATR) over the past year, gaining 13.0% versus a loss of 16.8%. Over five years, NATR leads with a -18.1% price change compared with -36.8% for IFRX. InflaRx N.V. is the larger company by market cap ($219.6 million vs $219.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | NATR |
|---|---|---|
| Share price | $1.49 | $12.47 |
| Market cap | $219.58M | $219.42M |
| 1-day change | -4.49% | -0.95% |
| YTD return | +54.46% | -41.66% |
| 1-year return | +13.04% | -16.79% |
| 5-year return | -36.84% | -18.09% |
| P/E ratio (TTM) | — | 12.35 |
| Forward P/E | — | 10.14 |
| EPS (TTM) | $-0.58 | $1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $28.14 |
| 52-week low | $0.798 | $12.31 |
| Distance from 52-week high | -49.47% | -55.69% |
| Analyst consensus | none | none |
| Avg. price target upside | +414.09% | +144.59% |
| Average volume | 794.10K | 159.62K |
| Shares outstanding | 147.37M | 17.60M |
| Employees | 65 | 806 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed NATR by 29.8 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Nature's Sunshine Products
NATR stock →Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company distributes general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision; and immune products to support and strengthen the human immune system.
Health Care · Biotechnology: Pharmaceutical Preparations · 806 employees
IFRX vs NATR FAQ
Which is bigger, InflaRx N.V. or Nature's Sunshine Products?
InflaRx N.V. (IFRX) is larger, with a market capitalization of $219.58M compared with $219.42M for Nature's Sunshine Products (NATR).
Which stock has performed better over the past year, IFRX or NATR?
IFRX returned +13.04% over the past 12 months, compared with -16.79% for NATR (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Nature's Sunshine Products in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.